与乳腺癌预后相关的生物学指标研究进展

被引：2

作者：

李桂梅

机构：

[1] 东南大学基础医学院南京

来源：

临床肿瘤学杂志 | 2002年 / 03期

关键词：

乳腺癌; 生物学指标; 预后;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

引用

页码：236 / 238

页数：3

共 6 条

[1] Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer [J].

Ceccarelli, C ;

Santini, D ;

Gamberini, M ;

Taffurelli, M ;

Chieco, P ;

Piana, S ;

Pileri, S ;

Marrano, D .

BREAST CANCER RESEARCH AND TREATMENT, 1999, 58 (02) :107-114

[2]

Quantitation of erbB-2 gene copy number in breast cancer by an improved polymerase chain reaction (PCR) technique, competitively differential PCR[J] . Guoren Deng,Young S. Kim.Breast Cancer Research and Treatment . 1999 (3)

[3] c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients [J].

Sabino De Placido ;

Chiara Carlomagno ;

Michelino De Laurentiis ;

Angelo Raffaele Bianco .

Breast Cancer Research and Treatment, 1998, 52 :55-64

[4]

Cathepsin D in primary breast carcinoma: Adverse prognosis is associated with expression of cathepsin D in stromal cells[J] . A. E. M. A. O’Donoghue,D. N. Poller,J. A. Bell,M. H. Galea,C. W. Elston,R. W. Blamey,I. O. Ellis.Breast Cancer Research and Treatment . 1995 (2)

[5]

A mouse model for breast cancer induced by amplification and overexpression of the neu promotor and transgene .2 Weinstein EJ,Kitsberg DI,Leder P. Mol Med . 2000

[6]

Novel mechanisms of antiprogestin action .2 Horwitz KB,Tung L,Takimoto GS. Acta Oncol . 1996

← 1 →